物质信息
ID:1053
名称和标识
商标名
LobakMiorilaxMuskelAlinamBanabinRilansylRilaxTranrilaxBanabil-sintyalMuskel-TrancopalRexanRillasolSuprotanTanafolTrancoteBanabin-syntyalBisinaChlomedinonMio-SedRilassolSupotranTrancopalTransanateBanabin-SintyalClorilaxMyolespenPhenarolRilaquilRilasol
别名
Chlormezanonum [INN-Latin]Clormezanone [DCIT]DichloromezanoneChlormethazanoneChlormethazoneClormetazanoneClormetazonChlormezanone [BAN:INN:JAN]ChlormezanonClormezanona [INN-Spanish]Chlormezanonedl-ChlormezanoneDichloromethazanone
IUPAC传统名
chlormezanone
IUPAC标准名
2-(4-chlorophenyl)-3-methyl-1$l^{6},3-thiazinane-1,1,4-trione
化合物性质
理化性质
疏水性(logP)
1.3
溶解度
2500 mg/L (hardly soluble)
描述信息
Drug Groups
approved; withdrawn
Description
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. [PubChem]
Indication
Used in the management of anxiety and in the treatment of muscle spasm.
Pharmacology
Chlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis).
Toxicity
Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
Affected Organisms
Humans and other mammals
References
•
Wollina U, Hipler UC, Seeling A, Oelschlager H: Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro. Skin Pharmacol Physiol. 2005 May-Jun;18(3):132-8.
[Pubmed]
•
Seeling A, Oelschlager H, Rothley D: [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone] Pharmazie. 2000 Apr;55(4):293-6.
[Pubmed]
•
Oelschlager H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, Machts H, Riederer H, Rackur H: [Cleavage and biotransformation of the central muscle relaxant chlormezanone] Pharmazie. 1998 Sep;53(9):620-4.
[Pubmed]
•
Gautier V, Vincon G, Demotes-Mainard F, Albin H: [Pharmacokinetics of chlormezanone in healthy volunteers] Therapie. 1990 Jul-Aug;45(4):315-9.
[Pubmed]
External Links
分子图谱
暂无数据
点击上传数据
参考文献
• Wollina U, Hipler UC, Seeling A, Oelschlager H: Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro. Skin Pharmacol Physiol. 2005 May-Jun;18(3):132-8. Pubmed
• Seeling A, Oelschlager H, Rothley D: [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone] Pharmazie. 2000 Apr;55(4):293-6. Pubmed
• Oelschlager H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, Machts H, Riederer H, Rackur H: [Cleavage and biotransformation of the central muscle relaxant chlormezanone] Pharmazie. 1998 Sep;53(9):620-4. Pubmed
• Gautier V, Vincon G, Demotes-Mainard F, Albin H: [Pharmacokinetics of chlormezanone in healthy volunteers] Therapie. 1990 Jul-Aug;45(4):315-9. Pubmed